Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Operating Expenses for 14 consecutive years, with $29.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 26.26% year-over-year to $29.9 million, compared with a TTM value of $140.0 million through Dec 2025, down 20.85%, and an annual FY2025 reading of $150.7 million, down 20.42% over the prior year.
  • Operating Expenses was $29.9 million for Q4 2025 at Enanta Pharmaceuticals, down from $33.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $58.1 million in Q4 2021 and bottomed at $29.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $47.9 million, with a median of $49.9 million recorded in 2021.
  • The sharpest move saw Operating Expenses skyrocketed 33.65% in 2021, then dropped 26.26% in 2025.
  • Year by year, Operating Expenses stood at $58.1 million in 2021, then fell by 7.68% to $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then fell by 23.42% to $40.5 million in 2024, then fell by 26.26% to $29.9 million in 2025.
  • Business Quant data shows Operating Expenses for ENTA at $29.9 million in Q4 2025, $33.5 million in Q3 2025, and $37.2 million in Q2 2025.